The FDA has cleared U.K.-based Adaptix to market a 3D X-ray system that, according to the company, images hands, feet and elbows “at a fraction of the radiation dose and per-study cost of traditional CT.”
The company, a subsidiary of the international engineering company Avingtrans, says the portable digital tomosynthesis (DT) equipment is its first offering in medical imaging.
Adaptix says its DT technology is already established in veterinary markets, and the new product’s approval for use in U.S. medicine marks “the first step in Adaptix delivering [on] its mission to transform radiology through provision of innovative, truly-portable 3D imaging technologies to healthcare providers.”
The company’s CEO, Mark Evans, adds that Adaptix will next aim at marketing DT equipment for other orthopedic indications as well as for chest imaging in intensive care and emergency settings.
“We see a future where 3D travels to the patient at the point of care throughout hospitals, clinics and primary care,” Evans says, “transforming patient pathways, improving patient experience and reducing the cost of care delivery.”
Full announcement here.
Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.